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platinum-DNA adducts with double-fluorescence video
microscopy
C Meijer1, EGE de Vries1, WA Dam1, MHF Wilkinson2, H Hollema3, HJ Hoekstra4 and NH Mulder1
Departments of 'Medical Oncology, 3Medical Microbiology, 3Pathology, and 4Surgical Oncology, University Hospital Groningen, The Netherlands
Summary To detect low-level DNA platination, a sensitive immunocyto- and histochemical technique was developed using a polyclonal
antibody. The antibody GPt, derived after immunization of rabbits with highly platinated DNA and purified with affinity chromatography,
detected the main platinum (Pt)-containing intrastrand and interstrand adducts. Double-fluorescence microscopy image analysis was used to
quantify Pt-DNA adducts with Hoechst 33258 fluorescence to locate the nuclei and with fluorescein isothiocyanate fluorescence to measure
the immunosignal. A two- to five-fold dose-dependent difference in the level of cisplatin (CDDP)-induced Pt-DNA adducts between a CDDP-
sensitive and -resistant human tumour cell line was detected. Large differences in Pt-DNA adduct levels after in vitro CDDP incubation
between human buccal cells, lymphocytes and biopsies of different tumour types were observed. Pt-DNA adduct levels were fivefold higher
in human testiculartumours than in colon tumours, representing CDDP-sensitive and -resistant tumours, respectively, in the clinic. These data
suggest the possibility of predictive testing by measuring Pt-DNA adduct levels. Pt-DNA adducts in patients after treatment with CDDP were
shown in normal buccal cells and in imprints of fresh tumour biopsies as well as in paraffin-embedded tumour cells. The analysis of Pt-DNA
adducts at a single-cell level in small samples of normal and tumour cells during and/or after treatment is feasible with GPt and will hopefully
enable more selective treatment of patients.
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CDDP and its analogues are among the most important chemo-
therapeutic drugs in clinical practice with a broad spectrum of
activity. Almost all patients treated for testicular cancer with
CDDP-containing combinations respond, and approximately 80%
are cured. In contrast, no cures can be obtained in the case ofcolon
cancer and most other solid tumours, even when initially sensitive
to this drug, for example in the case of small-cell lung cancer
(Loehrer and Einhorn, 1984). In all of these settings, a number of
patients will not respond to therapy, although side-effects will be
similar to those ofresponders. It would be desirable to be able to
predict response to therapy as, for non-responders, either dose
intensification or other forms of treatment would be preferable to
standard CDDP treatment.
In the past, rather unsuccessful attempts have been made to
predict responses to therapy. Studies were performed with detection
methods for cell kill (Hamburger and Salmon, 1977) or prolifera-
tion inhibition (Mosman, 1983; Weisenthal et al, 1983) in solid
tumour samples exposed to drugs in vitro. Attempts to predict the
effects oftreatment ofchildhood lymphoblastic leukaemia by expo-
sure of (non-proliferating) peripheral blood blast cells in vitro to
drugs before systemic treatment have been more successful (Pieters
et al, 1991). For solid tumours, some positive results have been
reported; the level of platinum (Pt)-DNA adducts in leucocytes of
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patients treated with CDDP was found to correlate with treatment
outcome (Poirier et al, 1985, 1987, 1992; Reed et al, 1986, 1987,
1988, 1990, 1993;Fichtinger-Schepman etal, 1987, 1990; Parkeret
al, 1991; Dabholkar etal, 1992). Until now, no serial measurements
of Pt-DNA adduct levels have been performed in tumour cells of
patients before, during and/or after CDDP treatment. Ideally, this
measurement should be performed before treatment (requiring in
vitro testing), but altematively it would still be worthwhile to obtain
a tumour sample early in the treatment.
An immunocyto- and histochemical technique was developed
with a new polyclonal antibody, GPt, which allows the detection
of low-level Pt-DNA adducts at a single-cell level in small
samples of a broad range of material. Double-fluorescence
microscopy image analysis was used for quantitation. The present
study describes this technique and its application under both in
vitro and in vivo conditions.
MATERIALS AND METHODS
Chemicals
CDDP and carboplatin were obtained from Bristol-Myers SAE
(Weesp, The Netherlands) and doxorubicin from Pharmacia,
Farmitalia Carlo Erba (Milan, Italy). RPMI-1640 medium and
fetal calf serum (FCS) were purchased from Life Technologies
(Paisley, UK). Human DNA, salmon sperm DNA, complete and
incomplete Freund's adjuvants, Tween-20, ethanolamine and
alkaline phosphatase conjugated goat anti-rabbit antibody were
obtained from Sigma (St Louis, MO, USA). Methylated bovine
serum albumin (mBSA) was obtained from Serva (Heidelberg,
Germany), p-nitrophenyl phosphate from Boehringer Mannheim
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(Mannheim, Germany), the DNA polymers poly(dG).poly(dC),
poly(dA-dG).(dC-dT), poly(dG-dC).poly(dG-dC) and cyanogen
bromide-activated Sepharose 4B from Pharmacia (Uppsala,
Sweden), guanidine-HCl from Merck (Darmstadt, Germany),
Hoechst 33258 (Hoechst) from Calbiochem (La Jolla, CA, USA),
fluorescein isothiocyanate (FITC)-conjugated swine anti-rabbit
antibody from Dakopatts (Glostrup, Denmark) and immunofluor
mounting medium from ICN Biomedicals (Costa Mesa, CA,
USA). BSA was provided by the CLB (Amsterdam, The
Netherlands) and human AB serum by the blood bank Groningen
(Groningen, the Netherlands).
Polyclonal antibody
Rabbits were immunized with 210 ,ug of Pt-DNA (CDDP-plati-
nated human DNA in a drug-nucleotide ratio of0.085) coupled to
210 gg mBSA in an emulsion with complete Freund's adjuvant,
administered as three injections intradermally at 10-day intervals.
Subsequently, a sustaining dose (210 jig Pt-DNA/210 gg mBSA
in incomplete Freund's adjuvant) was given intramuscularly every
6 weeks. Serum was collected 10 and 20 days after the intra-
muscular sustaining dose and screened for antibody production
by an enzyme-linked immunosorbent assay (ELISA).
The ELISA was performed according to Fichtinger-Schepman
et al (1985) with slight modifications and was used to select anti-
bodies and to characterize the adduct specificity of selected anti-
bodies. Microtitre plates were coated overnight at 370C with heat-
denatured CDDP-treated (3.3 and 16.5 jM, S h at 60°C) salmon
sperm DNA, with drug-nucleotide ratios of 0.0012 ± 0.0004
and 0.0082 ± 0.0022 (mean ± s.d.), respectively, by incubation
of0.05 jg of DNA solution in phosphate-buffered saline-I (PBS-
1) per well. After intensive washing, coated plates were used
immediately or stored at -200C (for a maximum of 14 days).
Plates were preincubated with 0.05% Tween-20 in PBS-I plus 1%
FCS (to block non-specific antibody binding), washed and
incubated with dilutions of serum or subsequently with affinity-
purified antibodies (see below) (1.5 h at 370C). Alkaline phos-
phatase conjugated second antibody together with the substrate
p-nitrophenyl phosphate were used to visualize the signal. The
absorbance was read at 405 nm using a scanning microtitre well
spectrophotometer. The amount of Pt-DNA adducts in the
samples was determined with the ELISA in the competitive mode.
This is identical to the direct ELISA except that the plates were
incubated with competition mixtures instead of antibody. The
competition mixtures contained fixed amounts of antibody and
various amounts of inhibitor that were pre-incubated for 1 h at
37°C before being added to the wells.
Preparation of platinated DNAs and polymers
Salmon sperm DNA and the DNA polymers poly(dG).poly(dC),
poly(dA-dG)-(dC-dT) and poly(dG-dC)-poly(dG-dC) were dis-
solved in Tris-EDTA buffer (1O mm Tris-HCl, 1 mm disodium
EDTA) and treated with CDDP (500jM) for 4 h at 370C. After
platination, the salmon sperm DNA was precipitated with ice-
cold 100% ethanol, washed twice with ice-cold 80% ethanol and
dissolved in water. The DNA polymers were used after dialysis
against Tris-EDTA buffer. In addition 2 x 108 cells of the human
small-cell lung cancer cell line GLC4 (Hospers et al, 1988, 1990;
Meijer et al, 1990) were treated with CDDP (500 jM) for 4 h at
37°C, washed three times with PBS-1 at 4°C followed by DNA
isolation as described before (Meijer et al, 1990). Both the salmon
sperm DNA and GLC4 DNA weredigested andprepared foradduct
separation by anion-exchange column chromatography [Mono Q
HR 5/5 column, particle size 10 jM (Pharmacia)] as described
previously (Fichtinger-Schepman et al, 1985; Meijer et al, 1990).
The Pt content of the DNA polymers and separated adducts was
determined by atomic absorption spectrometry (AAS). Total DNA
content was estimated by absorption at 260 nm. Adducts and DNA
polymers were used as inhibitors in the competitive ELISA.
Affinity chromatography
Purification of selected serum (based on ELISA) was performed
with affinity chromatography. DNA was platinated (with CDDP)
to a drug-nucleotide ratio of 0.0007 and dialysed against, succes-
sively, 0.1 M ammonium bicarbonate, water and coupling buffer
(0.1 M sodium bicarbonate, 0.5 M sodium chloride, pH 8.3). After
denaturation, the platinated DNA was coupled to (cyanogen
bromide)-activated Sepharose 4B; it was then washed, followed
by blocking of remaining active groups with ethanolamine (1 M,
pH 9.0). After intensive washing with low (0.1 M acetate buffer,
pH 4.0)- and high (coupling buffer, pH 8.3)-pH buffer solutions
followed by PBS-1, the column was packed and, after an addi-
tional wash procedure with PBS-1, was ready to use. At that time,
0.5 ml of serum was applied to the column. The affinity-purified
antibody GPt was eluted from the column by guanidine-HCl (4 M,
pH 3.1), dialysed against PBS-I and used as such.
Immunocyto- and histochemistry
Slides were air dried, fixed for 10 min in cold (-20°C) methanol
followed by 2 min in cold (-20'C) acetone, again air dried and
stored at -20'C until immunostaining. Paraffin-embedded biop-
sies, however, were fixed with formalin before embedding, stored
at room temperature and deparaffinized before immunostaining.
Upon staining, the slides were dried (except for paraffin-
embedded sections, which were used directly after being deparaf-
finized) washed with PBS-2 and incubated (30 min) with 1%
human AB serum and 1% BSA to block non-specific antibody
binding, followed by an overnight treatment with GPt (1:6) at
room temperature. After washing with PBS-2, the presence of
Pt-DNA adducts was visualized by incubation with a FITC label
and counterstained for DNA detection by Hoechst. An antifade
mounting medium was applied, and slides were stored at 4°C in
the dark until image analysis.
Image analysis
Double-fluorescence quantitative video microscopy was used to
measure the level of Pt-DNA adducts. At least 50-100 nuclei per
slide were processed for FITC and Hoechst fluorescence. The
Hoechst image served a twofold purpose. Firstly, it was used to
separate the nuclei from the background, using an automatic local
threshold selection method derived by Kittler et al (1985).
Secondly, it was used to provide a measure of the local DNA
surface density for each point within each nucleus. A new
approach to multiple fluorescence image analysis, fluorescence
linear fit microscopy (FLFM), was developed, which allowed the
quantitation of Pt-DNA adducts. Per nucleus, a linear fit of the
FITC fluorescence signal at each point as a function of the local
DNA surface density was performed. The resulting slope yields
the portion of FITC fluorescence attributable to the presence of
DNA and hence to the presence ofPt-DNA adducts. The intercept
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Table 1 Adduct recognition of the GPt antibody
Adduct Determined by Sensitivity
Monofunctional adduct Isolated monofunctional adduct Not detectable
Intrastrand AG adduct Isolated intrastrand AG adduct Not detectable
Poly(dA-dG).(dC-dT), platination level 14% lA50a = 0.5 ng Pt ml-'
Intrastrand GG adduct Isolated intrastrand GG adduct lA20b = 0.8 ng Pt ml-'
Poly(dG).poly(dC), platination level 25% IA50 = 0.5 ng Pt ml-1
Intrastrand adduct Isolated interstrand adduct IA20 = 3.75 ng Pt ml-'
Poly(dG-dC).poly(dG-dC), platination level 9% IA50 = > 500 ng Pt ml-1
alA50, amount of inhibitor with 50% inhibition in the competitive ELISA; blA20, amount of inhibitor with 20% inhibition in the competitive ELISA.
'5 }~~~~~~~~V
Figure 1 Immunostaining of GLC4 showed as combined FITC and Hoechst
images. Upper left, control cells (antibody background); upper right, cells
after a 4-h incubation with 3.3 gM CDDP; lower left, cells after a 4-h
incubation with 16.5 gM CDDP; lower right, cells after a 4-h incubation with
33 JM CDDP
yields the background fluorescence that is not attributable to DNA
or Pt-DNA adducts. A goodness-fit measure (mean absolute devi-
ates from the model must be less than 5) was used to detect and
eliminate cells in which the linear fit was disturbed automatically.
The median immunosignal showed a good correlation with the
exposure time used (data not shown). Therefore, when necessary,
the immunosignal was corrected for exposure time and/or nucleus
size. Once corrected, the immunosignal should be a linear function
of the amount of Pt-DNA adducts in each nucleus. Two different
kinds of saturation effects may occur: firstly, camera saturation
(overexposure), which can be avoided by appropriate adjustment
of exposure time; secondly, intrinsic saturation ofthe fluorescence
signal, can be the result of sterical hindrance, limiting the accessi-
bility of the antibodies to their targets, and of fluorophore-
fluorophore interactions at high dye concentrations. In case of in
vitro experiments, this can be avoided by adjustment of the extra-
cellular drug incubation concentrations. The use of a negative and
a positive standard control guaranteed comparable quantitation of
Pt-DNA adducts. Pretreatment samples served as corresponding
background controls. The fluorescence video microscopy system
Figure 2 Immunostaining of GLC4-CDDP showed as combined FITC and
Hoechst images. Upper left, control cells (antibody background); upper right,
cells after a 4-h incubation with 3.3 gM CDDP; lower left, cells after a 4-h
incubation with 16.5 gM CDDP; lower right, cells after a 4-h incubation with
33 gM CDDP
was based on personal computers equipped with image processing
boards (MVP-AT, Matrox, Dorval Quebec) and Fairchild CCD-
5000/1 cameras (Loral-Fairchild, Sunnyvale, CA, USA) as
described previously (Wilkinson et al, 1993; 1994).
Applicability of GPT
The applicability of GPt was evaluated in human cell lines, normal
cells (buccal cells and/or lymphocytes) and tumourcells (tumourcell
suspensions, imprints offresh tumourbiopsies orparaffin-embedded
tumourbiopsies) afterCDDP exposure in vitro or in vivo. GLC4 and
its 10-fold CDDP-resistant subline GLC4-CDDP (characterized by
an unchanged cellular Pt level, an increased glutathione level, a
decreased DNA platination and an increased DNA repair capacity;
Hospers et al, 1988, 1990; Meijer et al, 1990) were used to test the
immunocytochemical application of GPt in cell lines. [CDDP
concentrations inhibiting cell survival by 50% after a 4-h incubation
with CDDP were 3.0 and 27.3 [tM respectively (Meijer et al, 1990).]
Buccal cells and/or lymphocytes (isolated from heparinized blood
with a lymphoprep gradient; density 1.077 g ml' 20°C; Nycomed,
Pharma AS, Oslo, Norway) were sampled, subsequently washed
British Journal ofCancer (1997) 76(3), 290-298 0 CancerResearch Campaign 1997Immunocytochemical analysis ofcisplatin-inducedplatinum-DNA adducts 293
A
5
0
3.3 16.5 33
CDDP (gM)
Figure 3 Computer-analysed levels of Pt-DNA adducts in GLC4 (0-0) and
GLC4-CDDP (@) after immunostaining with GPt. FITC exposure time, 1 s;
mean nuclei size, 945 and 910 pixels for GLC4 and GLC4-CDDP respectively
with RPMI/3% FCS, followed by direct cytospin preparation in the
case of in vivo CDDP-exposed samples or incubation with CDDP
for the in vitro experiments, followed by cytospin preparation for
immunostaining. Fresh tumour samples taken before chemotherapy
were divided into parts and incubated with CDDP. Thereafter,
imprints were prepared forimmunostaining. Forthe measurement of
Pt-DNA adduct levels after in vitro CDDP exposure under similar
conditions, samples were incubated for4 h with 3.3, 16.5 and 33 gM
CDDP followed by washing, preparation, fixation and storage of
the slides at -20°C until immunostaining. Feasibility of predictive
testing was evaluated under the described in vitro conditions in
human testicular and colon tumours, representing, respectively,
CDDP-sensitive and -resistant tumour types in the clinic.
In vivo Pt-DNA adduct levels were determined in normal buccal
cells and/or tumour cells of four patients before, during and after
treatment with CDDP-containing chemotherapy. Chemotherapy
included 80-100 mg m-2 CDDP administered either over 5 days
(n = 2) or as a bolus infusion with an interval of 3 weeks (n = 2).
Pt-DNA adducts were also measured in sections of paraffin-
embedded tumour biopsies of patients who received hyperthermic
isolated limb perfusion with CDDP for extremity tumours
(CDDP dose ranged from 20 to 30 mg 1-' extremity volume)
(Guchelaar et al, 1992). Parallel sections were routinely stained
with haematoxylin-eosin to check the presence of tumour cells.
RESULTS
Antibody development
Serum was selected because of its high binding capacity for
low-level platinated DNA and its lack ofbinding to control DNA.
GPt was derived after purification of selected serum with affinity
chromatography. The detection limit of GPt in the ELISA was
B
25
20
._L
C
0
E
c
.5
a)
15
10
5
3.3 16.5 33
CDDP(gM)
Figure 4 (A) Immunostaining of buccal cells after in vitro CDDP exposure,
shown as combined FITC and Hoechst images. Upper left, control buccal
cells (antibody background); upper right, buccal cells after a 4-h incubation
with 3.3 gM CDDP; lower left, buccal cells after a 4-h incubation with 16.5 gM
CDDP; lower right, buccal cells after a 4-h incubation with 33 rm CDDP.
(B) The corresponding computer-analysed level of Pt-DNA adducts. FITC
exposure time, 0.1 s; mean nuclei size, 422 pixels
approximately 25 fmol of Pt per assay well, and stable detection
could be observed up to a drug-nucleotide ratio of0.001. GPt was
evaluated with various platinated adducts (isolated from GLC4)
and DNA polymers to detect both the intrastrand Pt-GG adducts
and interstrand cross-links in a pharmacologically relevant DNA
platination area at the adduct level (competitive ELISA, Table 1).
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Figure 5 (A) Immunostaining of lymphocytes after in vitro CDDP exposure,
shown as combined FITC and Hoechst images. Upper left, control
lymphocytes (antibody background); upper right, lymphocytes after a 4-h
incubation with 3.3gM CDDP; lower left, lymphocytes after a 4-h incubation
with 16.5 gM CDDP; lower right, lymphocytes after a 4-h incubation with
33 gM CDDP. (B) The corresponding computer-analysed level of Pt-DNA
adducts. FITC exposure time, 5s; mean nuclei size, 390 pixels
Immunocyto- and histochemical application of
GPt: in vitro DNA platination
Figures 1 and 2 show the combined Hoechst and FITC signals ofa
representative immunostaining experiment in GLC4 and GLC4-
CDDP respectively. Nuclear FITC fluorescence was almost nega-
tive in CDDP-untreated, GPt-treated cells (background control)
16.5 33
CDDP (gM)
Figure 6 Computer-analysed levels of Pt-DNA adducts, corrected for
exposure time and differences in cell size, after in vitro CDDP exposure of
human testicular tumours (0-0) and colon tumours (0-). Mean ± s.e.m.;
n = 3; FITC exposure time, 0.1-0.5 s; mean nuclei size, 790 and 772 pixels
for the testicular and colon tumours respectively
and increased dose-dependently in both cell lines. Immunostaining
followed by computer image analysis showed dose-response
curves (Figure 3) in both GLC4 and GLC4-CDDP for the CDDP
concentrations used and the median immunosignal of the nucleus.
There was a two- to five-fold difference in the level of Pt-DNA
adducts between the cell lines. Also carboplatin-induced DNA
platination could be detected (data not shown). Based on available
immunocytochemistry and atomic absorption spectrometry (AAS)
data for GLC4, the lower detection limit of the immunocyto-
chemical assay approaches 10 fmol of Pt per jg of DNA.
Reproducibility of the assay, tested by measuring Pt-DNA adduct
levels in four individually performed staining experiments of
GLC4, was calculated to be within 25% (coefficient of variance).
The observed saturation of fluorescence at high extracellular
CDDP incubation concentrations is clearly intrinsic to the spec-
imen and is not caused by camera saturation.
Figures 4 and 5 show photographs of representative immuno-
staining experiments and the corresponding computer analysis of
the level of Pt-DNA adducts in buccal cells and lymphocytes after
in vitro CDDP exposure. In contrast to the buccal cells, which
showed a high level ofPt-DNA adducts, lymphocytes showed a low
level of immunofluorescence (FITC exposure times were 0.1 s for
the buccal cells and 5 s for the lymphocytes). The level ofPt-DNA
adducts (corrected for exposure time and cell size) after in vitro
CDDP exposure was fivefold higher in human testicular tumours
than in colon tumour imprints (Figure 6). Large differences in
Pt-DNA adduct levels (corrected forexposure time and nuclei size)
after in vitro CDDP exposure were observed between cell lines,
buccal cells, lymphocytes and different tumour types (Figures 3-6).
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Table 2 In vivo Pt-DNA adduct levels determined in normal buccal cells
before, during and after chemotherapy. Chemotherapy included
80-100 mg m-2 CDDP administered over 5 days (A) or as a bolus infusion
with an interval of 3 weeks (B)
A
Time In days Patient A Patient B
1 Negative (-, n = 71)a Not determined
2 2.28 (16%, n= 60) 1.55 (25%, n= 57)
3 3.01 (11%, n= 90) 1.66 (13%, n= 63)
4 3.45 (15%, n= 77) 0.50 (36%, n= 64)
5 Not determined 1.71 (24%, n= 65)
8 0.18 (28%, n = 51) Not determined
B
Cycles of 3 weeks Patient C Patient D
1 1.97 (25%, n= 62) 1.37 (16%, n= 52)
2 11.7(16%, n=58) 0.85(11%, n=67)
3 Not determined 4.85 (19%, n= 57)
T I I I aMedian immunosignal of the nucleus (standard error in percentage, number
1 2 3 4 5 6 7 8 of nuclei determined). FITC exposure time, 5 s.
Days
Figure 7 Computer-analysed levels of Pt-DNA adducts, corrected for nuclei
size of samples of normal buccal cells (0-0) as well as imprints of a lymph
node (@-) of a seminoma patient. Samples were taken before and on days
1-4 of a 5-day CDDP regimen (20 mg m-2 CDDP perday) and 4 days after
the end of treatment. FITC exposure time, 1 s
In vivo DNA platination
Figure 7 shows in vivo Pt-DNA adduct levels measured in normal
buccal cells and in smears of a lymph node. Samples were collected
from a patient (patient A) with seminoma before and on days 1-4 of
a 5-day CDDP regimen (20 mg mi-2 CDDP perday) and4 days after
the end oftreatment. The level ofPt-DNA adducts increased during
the treatment in buccal and tumour cells in this patient, who was
cured by this treatment. The Pt-DNA adduct level declined in the
buccal cells but was still detectable 4 days after the last administra-
tion of CDDP. Pt-DNA adducts were also measured in buccal cells
of three other patients (Table 2). A non-increasing low level of
Pt-DNA adducts measured over 5 days was observed in samples of
a non-responding patient (patient B) with an extragonadal germ cell
tumour. Increasingly high levels ofPt-DNA adducts were observed
over two and three cycles (with an interval of 3 weeks) of CDDP-
containing chemotherapy in two responding patients with choriocar-
cinoma (patients C and D). Pt-DNA adducts were also measured in
paraffin-embedded human tumour samples after hyperthermic
isolated limb perfusion with CDDP. Pt-DNA adduct levels,
expressed as median immunosignal after 1 s FITC exposure time,
were 0.41 (n = 1) immediately after, 1.31 (n = 3) 3-6 weeks afterand
0.76 (n = 3) 3 months after perfusion. These levels were clearly
detectable and were similar to the Pt-DNA adduct level of GLC4
after a 4-h exposure to 3.3 gM CDDP. There was still a significant
level ofPt-DNA adducts detectable 3 months afterCDDPperfusion.
DISCUSSION
The existence ofnatural resistance or the development of acquired
resistance to CDDP is the major cause oftreatment failure with this
drug in solid tumours. Studies in a variety of cell lines have
revealed that several mechanisms can be involved in resistance to
CDDP, including decreased drug accumulation, increased detoxifi-
cation, decreased DNA platination and/or increased DNA repair
(Bedford et al, 1988; Andrews and Howell, 1990; Fry et al, 1991;
Sark et al, 1995). In almost all models, a combination of mecha-
nisms is found, often resulting in a reduced DNA platination.
Current information, however, suggests that not only the occur-
rence of adducts but also their quantity determine the fate of the
cell. Another important factor may be the degree of tolerance to
such damage or alternatively the occurrence ofapoptotic cell death.
For a long time, evaluation of the relationship between in vivo
DNA platination and response to chemotherapy has been limited
by the requirement of large quantities of human material for reli-
able measurements ofDNA platination by AAS. The development
of antisera against platinated DNA has opened the way for the
detection oflow-level Pt-DNA adducts in human material (Poirier
et al, 1982; Lippard et al, 1983; Fichtinger-Schepman et al, 1985;
Plooy et al, 1985; Sundquist et al, 1987; Terheggen et al, 1987,
1991; Tilby et al, 1991; Chao et al, 1994). Until now, no serial
measurements ofPt-DNA adducts have been performed in tumour
cells ofCDDP-treated patients.
In the present study, we describe the adaptation of a routine
immunocyto- and histochemical staining protocol using GPt, the
newly developed polyclonal antibody against platinated DNA,
allowing sensitive detection of Pt-DNA adducts at a single-cell
level in small samples of a broad range ofmaterial. Moreover, the
morphological localization ofPt-DNA adducts with this technique
allows analysis of tumour tissue and normal tissue. GPt, derived
after immunization ofrabbits with highly CDDP-platinated human
DNA and subsequent purification of serum by affinity chromatog-
raphy, was shown to detect the main Pt-containing intrastrand (Pt-
GG) and interstrand adducts. An immunocyto- and histochemical
technique was developed that allows the detection of low-level
Pt-DNA adducts. Multiple fluorescence video image analysis,
FLFM, was successfully used to quantitate the Pt-DNA adducts.
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In the cell lines GLC4 and GLC4-CDDP, the slopes derived from
FLFM correlated well with the more common and easier form of
fluorescence quantitation, i.e. by measuring mean surface fluores-
cence per nucleus. Although simpler to implement, the latter
method could not measure, and thereby correct for, background
fluorescence in morecomplicated slides, such as paraffin sections,
and moreovercould notautomatically eliminateobjects(where the
fluorescence model breaks down,by use ofagoodness-fit measure
(data not shown).
Differences in Pt-DNA adduct levels after in vitro CDDP
exposure between CDDP-sensitive and- resistant cell lines could
be clearly detected. DNA platination measurements with AAS
showed a 1.6-fold difference in DNA platination between GLC4
and the CDDP resistant GLC4-CDDP at thehighestCDDP incuba-
tion concentration used in the present study (Meijer et al, 1990).
Based on the available immunocytochemistry and AAS results
for GLC4, the detection limit of our immunocytochemical assay
approached 10 fmol ofPt perjg ofDNA [approximately 0.2 amol
ofPt per genome (nucleus)], which should allow the measurement
ofPt-DNA adducts after exposure to CDDP in vivo (Terheggen et
al, 1988). The at least 10-fold higher sensitivity compared with
AAS and thepossibility to measure Pt-DNA adducts inonly a few
cells (100-150 cells compared with 1-5 x l07cells needed for reli-
able AAS measurements) are important advantages and require-
ments for the determination of Pt-DNA adducts in biological
(patient) samples.
In vitro CDDP exposure revealed high platination levels in
buccal cells compared with lymphocytes. Terheggen et al (1988)
also reported a lower level of Pt-DNA adducts in human lympho-
cytes than in buccal cells after in vitro CDDP exposure. Apart
from differences in cellviability, noexplanation for this difference
in the level of in vitro Pt-DNA adducts between human buccal
cells and lymphocytes seems to be available. Pt-DNA adduct
levels after in vitro exposure ofleucocytes to CDDP were found to
correlate with Pt-DNA adduct levels ofleucocytes obtained from
the same patient after CDDP treatment (Fichtinger-Schepman et
al, 1990). In the present study, in vitro CDDP exposure ofsamples
from different human tumour types showed fivefold higher
Pt-DNA adduct levels in testicular tumours than in colon carci-
nomas. This suggests the possibility of predictive testing for this
method. A confirmatory study is required in which a variety of
tumours with known different degrees of sensitivity to CDDP
should be included.
Pt-DNA adduct levels in patients has, until now, predominantly
been studied by three groups, but only in leucocytes and never in
tumour cells of patients before, during or after Pt-containing
chemotherapy. The largest studies have been performed by Reed
and Poirier in over 100 patients with ovarian and/or testicular
cancer. In their studies, the quantity of measurable Pt-DNA
adducts in leucocytes, determined with ELISA in most cases,
increased as a function of cumulative dose of CDDP during
repeated daily infusion of the drug and over a longer period with
repeated cycles of administration. Pt-DNA adduct formation was
consistently and directly related to therapy response (Poirier et al,
1985, 1987, 1992; Reedetal, 1986, 1987, 1988, 1990; Parkeretal,
1991). More recently, this correlation has also been shown for
patients with 24 different types ofmalignancies. This suggests that
leucocytes may process DNA platination in a similar way to the
tumour, regardless ofthe tissue oforigin ofthe tumour(Dabholkar
et al, 1992; Reed et al, 1993). Furthermore, similar levels ofDNA
platination have been reported in tumour and bone marrow tissue
obtained at autopsy from Pt-treated patients (Reed et al, 1987;
Poirier etal, 1992). The same studies, however, also showed differ-
ences in DNA platination between various organs and human
tissues from the same patients. Fichtinger-Schepman et al (1985,
1989) used antibodies raised against synthetic haptens mimicking
the Pt-containing digestion products of DNA to detect the various
Pt-DNA adducts after chromatography of enzymatically digested
DNA samples, also by use ofthe ELISA (Plooy et al, 1985). They
also reported higher Pt-DNA adduct levels in the leucocytes of
testicular cancerpatients who showed a complete tumour response
than in the leucocytes of those with a partial response or progres-
sive disease. Substantial interindividual variation in Pt-DNA
adduct levels after treatment was observed, correlating with
Pt-DNA adduct levels obtained after in vitro CDDP exposure of
leucocytes from the same patients sampled before treatment
(Fichtinger-Schepman et al, 1990). Den Engelse et al used
immunodensitometry to study Pt-DNA adduct levels in buccal
cells after CDDP and/or carboplatin exposure (Terheggen et al,
1988; Gill et al, 1991; Blommaert et al, 1993). In addition, for
buccal cells, large interindividual differences in Pt-DNA adduct
levels were reported after carboplatin and/or CDDP treatment.
Pt-DNA adduct levels were found to be higher in partial respon-
ders than in non-responders (Blommaert et al, 1993). Human
buccal cells incubated in vitro with CDDP showed linear relation-
ships between Pt-DNA adduct levels and either CDDP concentra-
tion or incubation time. No quantitative correlation, however, was
found between in situ and in vitro Pt-DNA adduct levels
(Terheggen et al, 1988).
Only Fichtinger-Schepman et al (1990) have reported a case of
Pt-DNA adduct levels during treatment. They measured Pt-DNA
adducts in DNA isolated from a testicular tumour 3 days after the
first cycle of a 5-day CDDP regimen. The Pt-GG adduct level in
tumour tissue was 10-fold higher than in leucocytes during CDDP
treatment (Fichtinger-Schepman et al, 1990).
In the present study, only small series ofsamples were evaluated
for Pt-DNA adducts after treatment with CDDP in vivo. Pt-DNA
adducts could be clearly detected in buccal cells, tumour cells and
paraffin-embedded tumourbiopsies afterCDDP-containing therapy
and moreover, as far as was evaluable, was found tobe correlated to
response to chemotherapy. Additional information on this subject,
focusing on the quantity ofPt-DNA adducts after in vivo exposure
or the level of Pt-DNA adducts after in vitro CDDP exposure as a
measure fortherapy response in readily accessible tumourtissues, is
however needed. The method described in this study allows
analysis oflow-level Pt-DNA adducts at a single-cell level in small
samples after both in vitro and in vivo exposure to CDDP and,
therefore, may allow the measurement of the amount of Pt-DNA
adducts required to predict response to CDDP-based therapy.
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ABBREVIATIONS
CDDP, cisplatin; Pt, platinum; FCS, fetal calf serum; mBSA,
methylated bovine serum albumin; Hoechst, Hoechst 33258; FITC,
fluorescein isothiocyanate; ELISA, enzyme-linked immunosorbent
assay; PBS-1, phosphate-buffered saline 1(0.14 M sodiumchloride,
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2.7 mM potassium chloride, 6.4 mM disodium hydrogen phosphate,
1.5 mM potassium hydrogen phosphate, pH 7.4); PBS-2, phos-
phate-buffered saline 2 (0.15 M sodium chloride, 7.7 mm disodium
hydrogen phosphate, 1.6 mM potassium hydrogen phosphate,
pH 7.4); FLFM, fluorescence linear fit microscopy; AAS, atomic
absorption spectrometry
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